ProBioGen selected for development and large-scale manufacturing services
The Contract Development and Manufacturing Organization (CDMO) and technology provider will use its CHO.RiGHT expression platform for high-titer cell line development.
Immunogenesis — a spin-off of the MD Anderson Cancer Center, University of Texas — has selected ProBioGen for cell line development, process development and GMP manufacturing in 1,000-L bioreactor scale for their lead Immuno-Oncology candidate.
The lead candidate is a first-in-class monoclonal antibody with two different specificities resulted from R&D work at the MD Anderson Cancer Center, University of Texas.
Using its CHO.RiGHT expression platform for high-titer cell line development, ProBioGen will support the development and conduct large-scale manufacturing of Immunogenesis’ promising molecule in ProBioGen’s new facility.
Now, with two facilities in Berlin, ProBioGen is prepared to accommodate the increased demand for manufacturing.
Michael A. Curran, founder of Immunogenesis and associate professor at the MD Anderson Cancer Center, said: “With ProBioGen we found the right partner that has great scientific expertise and the ‘can-do’ mindset which we very much appreciate for this challenging step.”
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...